Technical Appendix
Technical Appendix Table 1 No change in duration *Systemic anthrax includes anthrax meningitis; inhalation, injection, gastrointestinal anthrax; and cutaneous anthrax with systemic involvement, extensive edema, or lesions of the head or neck. Boldface indicates preferred agent. Alternative selections are listed in order of preference for treatment for patients who cannot take first-line treatment, or if first-line treatment is unavailable. †Increased risk of seizures associated with imipenem/cilastatin treatment ‡Linezolid should be used with caution in patients with thrombocytopenia, as it may exacerbate it. Linezolid use for >14 d carries additional risk for hematopoietic toxicity. §A single 10-14 course of doxycycline is not routinely associated with tooth-staining. ¶Rifampin is not a protein synthesis inhibitor; however, it may be used in combination with other antimicrobials based on its in vitro synergy. No change on duration *Recommendations are specific to cutaneous anthrax in the setting of bioterrorism. Boldface indicates preferred agent. Alternative selections are listed in order of preference for treatment for patients who cannot take first-line treatment, or if first-line treatment is unavailable.. †Based on in vitro susceptibility data, rather than studies of clinical efficacy.
